ROCHE

📅 Upcoming

🕒 Recent(90d)

News

• MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troubles
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 2d ago
• Chutes & Ladders—Former Legend CEO lands at K2
  Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed…
  fiercebiotech · 2d ago
• Vaderis hauls in $152M to test an AKT-targeting drug
  The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.
  biopharma_dive · 4d ago
• IRBs have a problem. Can North Star’s nonprofit model save it?
  As institutional review boards face pressure from companies and ethicists, North Star Review Board offers a nonprofit model as more independent.
  stat · 4d ago
• Labcorp nabs FDA green light for BRAF melanoma diagnostic
  The FDA has signed off on Labcorp’s companion diagnostic for patients with advanced melanoma carrying certain BRAF variants.
  fiercebiotech · 5d ago
• FDA issues alert in wake of BD recall of faulty needle sets
  The FDA’s Center for Devices and Radiological Health issued an early alert for Becton Dickinson’s Intraosseous Vascular Access system needle sets in the wake of four deaths and 45 serious injuries…
  fiercebiotech · 5d ago
• Why Big Pharma is chasing the industry’s most-powerful supercomputer
  Bristol Myers Squibb is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.
  biopharma_dive · 8d ago
• Roche adds cyclospora PCR tests as outbreak widens
  Roche is launching new tests for cyclospora as an outbreak linked to iceberg lettuce from Mexico continues to spread across U.S. states.
  fiercebiotech · 8d ago
• Attovia adds to biotech IPO momentum with $289M offering
  The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.
  biopharma_dive · 10d ago
• Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
  The anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…
  biospace · 11d ago